(3R,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol Hydrate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol Hydrate
• 英文别名: (3R,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol;hydrate
• 化学式: C6H14O6
• 分子量: 182.17
• InChiKey: BNRKZHXOBMEUGK-GZIFQTRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.02
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  91.2
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  sodium methylate 、 allyl 2-O-acetyl-3,4-di-O-benzyl-α-L-rhamnopyranoside 在 H+ 、 methanol-dichloromethane 、 silica gel 、 乙酸乙酯 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 以to give the alcohol 58 in the form of a colorless oil (39.2 g, 92% or 61% starting from commercial L-rhamnose 27)的产率得到
  参考文献：
  名称：

  GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X

  摘要：

  本发明涉及从糖类衍生的化合物，这些化合物再现志贺氏菌属3a和X血清型的表位，以及将其用于制备疫苗组分的用途。更具体地，本发明的主题涉及新型的糖醛酸化合物，包括下文所述的寡糖或多糖，以及合成这些寡糖或多糖和糖醛酸偶联物的方法，这些寡糖或多糖的衍生物，含有这些衍生物的组合物，以及将糖醛酸偶联物用于疫苗接种目的的用途。最后，本发明涉及使用一个或多个寡糖或多糖或其共轭物诊断志贺氏菌属感染的方法。

  公开号：

  US20100239584A1

文献信息

• Lectin-directed prodrug delivery system
  申请人：Davis Guy Benjamin

  公开号：US20070253942A1

  公开（公告）日：2007-11-01

  The invention provides a kit for lectin-directed prodrug delivery comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug and thereby release the drug. The glycoconjugate generally comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin. The invention also provides novel glycoconjugates and novel methods of synthesizing prodrugs.

  本发明提供了一种用于凝集素定向前药递送的试剂盒，包括前药和凝集素定向的糖基结合物，其中糖基结合物适应于裂解前药并释放药物。糖基结合物通常包括与结合到凝集素的碳水化合物基团偶联的酶。本发明还提供了新型糖基结合物和新型合成前药的方法。
• Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
  申请人：Mulard Laurence

  公开号：US08815239B2

  公开（公告）日：2014-08-26

  The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

  本发明涉及从糖中衍生的化合物，其重现志贺菌弗氏菌血清型3a和X的表位，并用于制备疫苗组合物。更具体地，本发明的主题涉及新型糖链共轭化合物，包括下文所述的寡糖或多糖，以及合成这些寡糖或多糖和糖链共轭物的方法，这些寡糖或多糖的衍生物，含有它们的组合物，以及使用糖链共轭物进行疫苗接种的用途。最后，本发明涉及使用一个或多个寡糖或多糖或其共轭物诊断志贺菌弗氏菌感染的方法。
• GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X
  申请人：INSTITUT PASTEUR

  公开号：US20150050282A1

  公开（公告）日：2015-02-19

  The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

  本发明涉及从糖衍生物中复制Shigella flexneri 3a和X血清型表位的化合物，以及用于制备疫苗组分的使用方法。更具体地说，本发明的主题涉及新型糖连接化合物，包括下文描述的寡糖或多糖，以及合成这些寡糖或多糖和糖连接物的方法，这些寡糖或多糖的衍生物，含有它们的组合物，以及将糖连接物用于疫苗接种目的的用途。最后，本发明涉及使用一种或多种寡糖或多糖或其共轭物来诊断Shigella flexneri感染的方法。
• LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM
  申请人：ISIS INNOVATION LIMITED

  公开号：EP1372734A1

  公开（公告）日：2004-01-02
• [EN] LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM<br/>[FR] SYSTEME D'ADMINISTRATION DE PROMEDICAMENT ORIENTE LECTINE
  申请人：ISIS INNOVATION

  公开号：WO2002080980A1

  公开（公告）日：2002-10-17

  The invention provides a kit for lectin-directed prodrug delivery comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug and thereby release the drug. The glycoconjugate generally comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin. The invention also provides novel glycoconjugates and novel methods of synthesizing prodrugs.